A new computational study has found that goniothalamin — a natural plant compound — binds tightly to two critical bacterial proteins in drug-resistant Staphylococcus aureus and Escherichia coli , suggesting it could form the basis of a new class of antibacterial agents that work differently from conventional antibiotics and may be less likely to drive resistance.
The study, "Integrated Bioinformatic Modeling of Goniothalamin as a Dual-target Medicinal Chemistry Candidate against Antibiotic-resistant Staphylococcus aureus and Escherichia coli," was co-authored by Nawan Nawan, Septi Handayani, and Agnes Immanuela Toemon, and published in The Open Medicinal Chemistry Journal.
Antibiotic resistance – a growing problem
Antimicrobial resistance is escalating worldwide, leaving fewer effective treatment options. S. aureus and E. coli are two of the most problematic pathogens, often resistant to multiple drug classes. Conventional antibiotics target essential survival processes, which accelerates resistance. Anti‑virulence strategies — disabling disease-causing mechanisms rather than killing bacteria outright—offer a promising alternative. Goniothalamin, a plant-derived compound, was explored here for its antibacterial potential.
Using bioinformatics modeling
Researchers in Indonesia used bioinformatics tools to predict and model goniothalamin’s interactions with bacterial proteins. Target prediction identified two key proteins:
Molecular docking simulations assessed binding strength, while selectivity was tested against human proteins to evaluate safety. Reverse vaccinology was also applied to identify antigenic regions that could complement drug development.
What the Results Showed
Docking simulations revealed strong binding affinities: – 4.935 kcal/mol for agrA and –4.739 kcal/mol for ftsZ. Hydrophobic interactions dominated, suggesting stable and selective binding. Importantly, goniothalamin showed no significant affinity for human JAK2, indicating selectivity for bacterial targets. Antigenic regions identified in bacterial proteins further suggest potential synergy with vaccine approaches.
A potential antibacterial lead
The findings position goniothalamin as a promising antibacterial lead with a dual-target mechanism: reducing virulence in S. aureus and blocking cell division in E. coli . This dual action could make resistance harder to develop. The anti‑virulence angle is especially significant, as it may reduce pathogenicity without driving resistance as strongly as conventional antibiotics.
The study is computational and requires laboratory validation. The researchers mention that future work must test goniothalamin against live bacterial cultures, assess its effects on agrA and ftsZ, evaluate toxicity in cell and animal models, and study pharmacokinetics. Only then can its clinical potential be determined.
Article title: Integrated Bioinformatic Modeling of Goniothalamin as a Dual-target Medicinal Chemistry Candidate against Antibiotic-resistant Staphylococcus aureus and Escherichia coli
DOI: 10.2174/0118741045491054260619064621
Read the published article here: https://bit.ly/4dfTctt
The Open Medicinal Chemistry Journal
10.2174/0118741045491054260619064621
Integrated Bioinformatic Modeling of Goniothalamin as a Dual-target Medicinal Chemistry Candidate against Antibiotic-resistant Staphylococcus aureus and Escherichia coli